摘要
目的分析33例慢性乙型肝炎(CHB)患者应用聚乙二醇干扰素治疗的效果。方法33例CHB患者均采用聚乙二醇干扰素180μg皮下注射,每周1次,连续48周。检测治疗前后HBsAg定量、HBV DNA定量、CD4+T细胞及CD8+T细胞和调节性T细胞(Treg细胞)百分率,分析治疗前HBsAg、HBV DNA、免疫状态与HBsAg阴转的关系。结果 CD4+T细胞百分率阴转组高于未阴转组[(41.09±10.25)%vs.(31.86±7.84)%](P<0.05);CD8+T细胞百分率阴转组低于未阴转组[(20.86±5.47)%vs.(28.38±6.46)%](P<0.05)。HBsAg 1-150IU/ml组阴转率为58.3%,高于151-500IU/ml组的11.1%和501-2500IU/ml组的8.3%(P<0.05)。CHB患者CD4+T细胞百分率与HBsAg水平呈负相关(P<0.05)。结论 HBsAg<500IU/ml及处于非免疫耐受状态可作为应用聚乙二醇干扰素抗病毒治疗的优选人群。
Objective To analyze the efficacy of pegylated interferon α-2a in the treatment of 33 patients with chronic hepatitis B（CHB）. Methods Pegylated interferon α-2a 180μg was injected weekly for 48 weeks in 33 CHB patients. The HBsAg, HBV DNA and percentages of CD4＋ T cell, CD8＋ T cell and Treg cell were detected. The relationship of HBsAg, HBV DNA and immune state with HBsAg seroconversion before treatment was analyzed. Results The CD4＋ T cell percentage of patientes with HBsAg seroconversion was significantly higher than that of those with no HBsAg seroconversion[-（41.09±10. 25） % vs. （31.86 ±7.84） %] （P〈0. 05）. The CD8＋ T cell percentage of patientes with HBsAg seroeonversion was significantly lower than that of those with no HBsAg seroeonversionr（20. 86±5. 47） % vs. （28. 38±6.46）%] （P〈0. 05）. The HBsAg seroconversion rate in those with HBsAg of 1-150 IU/ml was 58.3% ,which was significantly higher than 11.1% in those with HBsAg of 151-500 IU/m and 8.3% in those with HBsAg of 501-2500 IU/ml（P〈0.05）. The percentage of CD4＋ T cells was negatively correlated with HBsAg level（P〈0. 05）. Conclusion CHB patients with HBsAg〈500 IU/ml and without a state of immune intolerance can he taken as the candidates for the use of pegylated interferon α-2a.
出处
《江苏医药》
CAS
北大核心
2014年第11期1277-1279,共3页
Jiangsu Medical Journal
基金
江苏省社会发展基金(BE2010650)
